Stockscreener 앱 받기
1.60
6.98%
-0.12
전일 마감가:
$1.72
열려 있는:
$1.74
하루 거래량:
2.35M
Relative Volume:
1.25
시가총액:
$425.86M
수익:
$92.67M
순이익/손실:
$-288.81M
주가수익비율:
-1.4744
EPS:
-1.0852
순현금흐름:
$-295.51M
1주 성능:
-11.60%
1개월 성능:
-14.44%
6개월 성능:
-0.62%
1년 성능:
-4.76%
1일 변동 폭
$1.59
$1.74
1주일 범위
$1.59
$1.82
52주 변동 폭
$1.175
$2.58
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
명칭
Autolus Therapeutics Plc Adr
전화
44 20 3829 6230
주소
THE MEDIAWORKS, LONDON
Compare AUTL vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.60 | 425.86M | 92.67M | -288.81M | -295.51M | -1.0852 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | H.C. Wainwright | Buy |
| 2024-11-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-15 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-03-27 | 재개 | Wells Fargo | Overweight |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2021-06-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | JP Morgan | Overweight |
| 2020-07-22 | 개시 | SunTrust | Buy |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2019-09-23 | 개시 | Needham | Buy |
| 2019-05-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-24 | 개시 | H.C. Wainwright | Buy |
모두보기
Autolus Therapeutics Plc Adr 주식(AUTL)의 최신 뉴스
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions - Simply Wall Street
Autolus Therapeutics Executive Reports RSU Vesting and Share Sale in Form 4 Filing - Kalkine Media
Autolus Therapeutics (AUTL) insider reports 20,000 RSUs - Stock Titan
Autolus (NASDAQ: AUTL) holder plans ADS sale tied to tax on vested stock - Stock Titan
Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year HighStill a Buy? - MarketBeat
Alphabet Inc. Takes Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 6.3% HigherStill a Buy? - MarketBeat
Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan
Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7%Here's Why - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat
Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - marketbeat.com
Autolus Secures New $250 Million Financing and Warrants - The Globe and Mail
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap UpStill a Buy? - MarketBeat
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors - The Manila Times
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout Continues - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesRevenue Breakdown Analysis - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesShare Dilution Risk - www.dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesEPS Consistency Score - dars.gov.et
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7%Time to Sell? - MarketBeat
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autolus awards stock grants to 13 new employees - Stock Titan
AUTLAutolus Therapeutics plc ADR Options - Finviz
Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL) - TradingView
Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to book forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to sales forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to earnings forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Enterprise value to EBITDA forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics Receives Prix Galien UK Award - GlobeNewswire Inc.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Autolus Therapeutics releases annual report and schedules shareholder meeting - Investing.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
AUTL - Finviz
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) to cut 13% of staff, save $15M - Stock Titan
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) registers $150M shelf for shares, ADSs, debt - Stock Titan
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data - Yahoo Finance
Autolus Therapeutics Plc Adr (AUTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Autolus Therapeutics Plc Adr 주식 (AUTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Piccina Cintia | U.S. CCO & Country Gen Manager |
Sep 02 '26 |
Sale |
2.34 |
6,713 |
15,682 |
13,287 |
| Piccina Cintia | Officer |
Sep 02 '26 |
Proposed Sale |
2.34 |
6,713 |
15,679 |
0 |
4.22%
자본화:
|
볼륨(24시간):